Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

The Lancet Oncology

Volumn 14, Issue 1, 2013, Pages 72-80

  Mackey, John R ^a   Martin, Miguel ^b   Pienkowski, Tadeusz ^c   Rolski, Janusz ^d   Guastalla, Jean Paul ^e   Sami, Amer ^f   Glaspy, John ^g   Juhos, Eva ^h   Wardley, Andrew ⁱ   Fornander, Tommy ^j   Hainsworth, John ^k   Coleman, Robert ^l   Modiano, Manuel R ^m   Vinholes, Jeferson ⁿ   Pinter, Tamas ^o   Rodríguez Lescure, Álvaro ^p   Colwell, Bruce ^q   Whitlock, Pierre ^r   Provencher, Louise ^s   Laing, Kara ^r   Walde, David ^t   Price, Chris ^u   Hugh, Judith C ^t   Childs, Barrett H ^v   Bassi, Kimberly ^v   Lindsay, Mary Ann ^w   Wilson, Véronique ^w   Rupin, Matthieu ^w   Houé, Vincent ^w   Vogel, Charles ^x   more..

^a CROSS CANCER INSTITUTE   (Canada)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c European Health Centre   (Poland)

^d Podkarpackie Centrum Onkologii   (Poland)

^e CENTRE LÉON BÉRARD   (France)

^f Saskatoon Cancer Center   (Canada)

^g Translational Oncology Research International   (United States)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j STOCKHOLM SÖDER HOSPITAL   (Sweden)

^k SARAH CANNON RESEARCH INSTITUTE   (United States)

^l WESTON PARK HOSPITAL   (United Kingdom)

^m Arizona Clinical Research Center   (United States)

ⁿ Clínica de Oncologia de Porto Alegre Clinionco Ltda   (Brazil)

^o Endocrinology and Diabetology   (Hungary)

^p HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^q QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^r Centre d'Oncologie Dr Leon Richard ^*  (Canada)

^s LAVAL UNIVERSITY   (Canada)

^t Algoma District Cancer Program   (Canada)

^u BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^v SANOFI   (France)

^w Translational Research In Oncology   (Canada)

^x Lynn Cancer Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HORMONE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 84871712569     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70525-9     Document Type: Article

References (31)

1. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26:44-53.
2. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
3. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast cancinomas distinguished tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
5. Common toxicity criteria manual, version 1.0 1982, National Cancer Institute, National Cancer Institute, Bethesda.
6. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
7. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006, 17:1205-1212.
8. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942. Early Breast Cancer Trialists' Collaborative Group.
9. Martin M, Segui MA, Anton A, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 2010, 363:2200-2210.
10. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005, 23:8597-8605.
11. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.
12. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007, 99:196-205.
13. Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3066-3071.
14. Masugata H, Senda S, Goda F, et al. Influences of hypertension and diabetes on normal age-related changes in left ventricular function as assessed by tissue Doppler echocardiography. Clin Exp Hypertens 2009, 31:400-414.
15. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007, 50:1435-1441.
16. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
17. Bonneterre J, Roche H, Kerbrat P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004, 22:3070-3079.
18. Doroshow JH Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983, 43:460-472.
19. Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
20. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002, 21. (abstr 141).
21. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005, 23:4287-4297.
22. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
23. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90:1361-1370.
24. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J Natl Cancer Inst 2000, 92:1991-1998.
25. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006, 354:2103-2111.
26. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100:14-20.
27. Press MF, Sauter G, Buyse M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011, 29:859-867.
28. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011, 29:1578-1586.
29. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 2011, 128:401-409.
30. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27:1177-1183.
31. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006, 24:5381-5387.